SC66 is primarily used in research settings for its ability to modulate protein kinase B (Akt) signaling pathways. It functions as a selective inhibitor that disrupts Akt activation by preventing its phosphorylation, making it a valuable tool in studying cell survival, proliferation, and apoptosis. Due to its role in inhibiting Akt, SC66 has drawn interest in cancer research, particularly in preclinical studies exploring its potential to enhance the effectiveness of chemotherapy and radiation by sensitizing tumor cells. It has shown activity in models of various cancers, including glioblastoma and leukemia, where aberrant Akt signaling contributes to treatment resistance. SC66 is not used clinically but remains an important compound for investigating targeted cancer therapies and signaling pathway dynamics in cellular models.